CAR-T Cell Therapy for DLBCL: How It Works and Who Qualifies

Research-informed explainer — last updated April 12, 2026

CAR-T cell therapy has transformed outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), producing durable remissions in roughly 40% of patients who previously had no good options after two lines of chemotherapy. Three distinct CAR-T products are now FDA-approved for this disease, each with a different manufacturing profile and side-effect pattern — and choosing among them requires specialist input.

This article draws on published research from five hematologists who have led or contributed to the pivotal trials that define CAR-T practice today. Patrick Stiff, MD, Professor of Hematology and Oncology at Loyola University and Director of the Cardinal Bernardin Cancer Center, contributed to the ZUMA-1 pivotal trial of axicabtagene ciloleucel (axi-cel) — the study that earned the first FDA approval for CAR-T in DLBCL and has accumulated 5,742 citations in the medical literature. Stephen Schuster, MD, Robert and Margarita Louis-Dreyfus Professor at the Abramson Cancer Center at the University of Pennsylvania, led the JULIET trial of tisagenlecleucel (tisa-cel), which has been cited nearly 3,939 times and produced the longest durability data for any CAR-T product in DLBCL. Leo Gordon, MD, Professor at Northwestern's Feinberg School of Medicine, co-investigated the TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel), a study cited 2,249 times that demonstrated excellent safety with a distinct manufacturing approach. David Miklos, MD, PhD, James and Katherine Lau Professor at Stanford, published real-world consortium data showing how axi-cel performs outside the controlled trial setting. Richard Champlin, MD, at MD Anderson Cancer Center, has contributed foundational transplant research and published on next-generation NK-cell CAR therapies that represent the frontier beyond current approved products.

What is CAR-T cell therapy?

CAR-T stands for chimeric antigen receptor T-cell therapy. The process begins with leukapheresis — a procedure that filters a patient's own white blood cells from the bloodstream over a few hours. T cells are isolated from that collection and sent to a manufacturing facility, where a gene is inserted that encodes a synthetic receptor (the chimeric antigen receptor) designed to recognize CD19, a protein found on the surface of most B-cell lymphomas including DLBCL.

The engineered cells are then multiplied into hundreds of millions and infused back into the patient — typically three to four weeks after the initial collection. Before infusion, patients receive a short course of lymphodepleting chemotherapy (usually fludarabine and cyclophosphamide) to make space for the CAR-T cells and reduce the immune environment that might suppress them. The CAR-T cells then proliferate in the body and attack any cell carrying CD19.

The three FDA-approved products for DLBCL

Axicabtagene ciloleucel (axi-cel, Yescarta) was the first CAR-T approved for DLBCL, based on the ZUMA-1 trial. In that study of 101 patients with refractory large B-cell lymphoma, the overall response rate was 83% and the complete response rate was 58%. The long-term follow-up published in The Lancet Oncology showed that 39% of patients remained in ongoing response at a median follow-up of 27 months — meaningful durability in a population where prior median survival was measured in months.

Tisagenlecleucel (tisa-cel, Kymriah) was validated in the international JULIET trial led by Dr. Schuster. Among 93 infused patients with relapsed or refractory DLBCL, the overall response rate was 52% and the complete response rate was 40%. The long-term JULIET follow-up published in The Lancet Oncology in 2021 found that remissions in complete responders were highly durable: the 12-month relapse-free survival rate was 65% among those who had achieved a complete response. Tisa-cel has a longer manufacturing turnaround than axi-cel, which can be a practical consideration for patients with rapidly progressing disease.

Lisocabtagene maraleucel (liso-cel, Breyanzi) was studied in the TRANSCEND NHL 001 trial investigated by Dr. Gordon. Among 269 patients across a range of DLBCL subtypes, the overall response rate was 73% and the complete response rate was 53%. Liso-cel uses a defined 1:1 ratio of CD4 and CD8 T cells in manufacturing, which is associated with a lower rate of severe cytokine release syndrome (CRS) than axi-cel in cross-trial comparisons.

Real-world vs. trial results

Trials enroll carefully selected patients. Dr. Miklos and colleagues at 17 US academic centers published a real-world consortium study of 295 patients treated with standard-of-care axi-cel outside of a clinical trial. The safety and efficacy outcomes were comparable to ZUMA-1, with an overall response rate of 81% and complete response rate of 64% — reassuring evidence that trial results translate to routine practice in experienced centers.

Who is a good candidate?

Current FDA approvals cover adults with DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma that has relapsed or is refractory after at least two prior lines of systemic therapy, including at least one anti-CD20 antibody and one anthracycline. All three products have also received approval for use as second-line therapy in patients who relapse within 12 months of first-line chemoimmunotherapy — a major expansion of eligibility supported by randomized trial data published after the initial approvals.

Key eligibility factors physicians evaluate include:

• Performance status (ECOG 0-1 preferred, though centers increasingly treat ECOG 2 patients)
• Organ function (adequate cardiac, hepatic, and renal function)
• Absence of active uncontrolled infection
• Absence of active CNS lymphoma at the time of treatment
• Ability to tolerate lymphodepleting chemotherapy

Age alone is not a disqualifier. Patients in their 70s and 80s have been successfully treated, provided their overall functional status is adequate.

Side effects to know

The two most important toxicities are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

CRS occurs when the activated CAR-T cells release large quantities of inflammatory cytokines. It typically begins within the first few days of infusion and can range from mild fever to severe respiratory compromise and low blood pressure requiring ICU care. Severe CRS (grade 3 or higher) occurred in approximately 13% of ZUMA-1 patients and 22% of JULIET patients. It is managed with tocilizumab, an IL-6 receptor blocker, with escalation to corticosteroids for refractory cases.

ICANS manifests as confusion, difficulty with language, tremor, or in severe cases, seizures and cerebral edema. Severe ICANS occurred in about 28% of ZUMA-1 patients and 13% of JULIET patients. Most cases resolve with corticosteroids. Brain tumor specialists are involved in monitoring and management at accredited centers.

Emerging options: NK-cell CAR therapies

Dr. Champlin and colleagues published a landmark study in the New England Journal of Medicine on CAR-transduced NK cells derived from cord blood — a different cellular platform that does not require patient-derived cells, potentially allowing off-the-shelf manufacturing. In the initial trial of 11 patients with CD19-positive hematologic malignancies, 8 responded (73%), with no CRS and no neurotoxicity observed. This approach is still experimental but represents one of the most promising next steps for patients who fail or are ineligible for autologous CAR-T.

Questions to ask your doctor

• Which CAR-T product is available at this center, and which do you recommend for my specific situation?
• How quickly can my cells be collected and manufactured, and what will we do to control my lymphoma while we wait?
• What is my risk of cytokine release syndrome or neurotoxicity, and how will it be managed?
• Does my disease biology (cell of origin, MYC/BCL2 double-hit status) affect my expected response to CAR-T?
• Am I eligible for CAR-T as second-line therapy rather than waiting until a third relapse?
• What clinical trials are currently open for patients who do not respond to or relapse after CAR-T?

The bottom line

CAR-T cell therapy has converted a disease with a median survival of months into one with durable long-term remissions for approximately 40% of treated patients. Three products are FDA-approved for DLBCL, each with distinct manufacturing, efficacy, and safety profiles. Eligibility has expanded — second-line use is now approved — and real-world data confirm that results match what clinical trials demonstrated. Evaluation by a hematologist at a CAR-T-accredited center is the critical first step for any patient with relapsed or refractory DLBCL.